27 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020

SYMLIN is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug.

This drug has thirty-two patent family members in sixteen countries.

See drug price trends for SYMLIN.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pramlintide acetate profile page.

TECFIDERA is a drug marketed by Biogen Idec Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-nine patent family members in thirty-three countries. There has been litigation on patents covering TECFIDERA

See drug price trends for TECFIDERA.

The generic ingredient in TECFIDERA is dimethyl fumarate. There are seventy-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dimethyl fumarate profile page.

CETROTIDE is a drug marketed by Emd Serono Inc. There is one patent protecting this drug.

This drug has twenty-eight patent family members in twenty-two countries.

See drug price trends for CETROTIDE.

The generic ingredient in CETROTIDE is cetrorelix. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the cetrorelix profile page.

OMTRYG is a drug marketed by Osmotica.

This drug has twenty-eight patent family members in twenty-two countries.

The generic ingredient in OMTRYG is omega-3-acid ethyl esters type a. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omega-3-acid ethyl esters type a profile page.

BEVESPI AEROSPHERE is a drug marketed by Astrazeneca Pharms. There are six patents protecting this drug.

This drug has one hundred and ten patent family members in twenty-seven countries.

See drug price trends for BEVESPI AEROSPHERE.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

RESCRIPTOR is a drug marketed by Viiv Hlthcare. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty countries.

See drug price trends for RESCRIPTOR.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this generic product. Additional details are available on the delavirdine mesylate profile page.

KOVANAZE is a drug marketed by St Renatus. There are three patents protecting this drug.

This drug has twenty-three patent family members in thirteen countries.

The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.

FIRAZYR is a drug marketed by Shire Orphan Therap. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fourteen patent family members in thirty-three countries. There has been litigation on patents covering FIRAZYR

See drug price trends for FIRAZYR.

The generic ingredient in FIRAZYR is icatibant acetate. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the icatibant acetate profile page.

CARDIOTEC is a drug marketed by Bracco. There is one patent protecting this drug.

This drug has ten patent family members in seven countries.

The generic ingredient in CARDIOTEC is technetium tc-99m teboroxime kit. There are four drug master file entries for this API. Additional details are available on the technetium tc-99m teboroxime kit profile page.

TROXYCA ER is a drug marketed by Pfizer Inc. There are two patents protecting this drug.

This drug has ten patent family members in six countries.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this API. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

YOSPRALA is a drug marketed by Genus Lifesciences. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries. There has been litigation on patents covering YOSPRALA

See drug price trends for YOSPRALA.

The generic ingredient in YOSPRALA is aspirin; omeprazole. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the aspirin; omeprazole profile page.

CYSTARAN is a drug marketed by Leadiant Biosci Inc.

This drug has forty-five patent family members in twenty-three countries.

See drug price trends for CYSTARAN.

The generic ingredient in CYSTARAN is cysteamine hydrochloride. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

LUMASON is a drug marketed by Bracco. There is one patent protecting this drug.

This drug has one hundred and forty-one patent family members in twenty-eight countries.

See drug price trends for LUMASON.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

SYNRIBO is a drug marketed by Teva Pharms Intl. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in nineteen countries.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omacetaxine mepesuccinate profile page.

IONSYS is a drug marketed by The Medicines Co. There are twelve patents protecting this drug.

This drug has one hundred and seventy-five patent family members in thirty-three countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fentanyl hydrochloride profile page.

POMALYST is a drug marketed by Celgene. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and forty patent family members in forty-three countries. There has been litigation on patents covering POMALYST

See drug price trends for POMALYST.

The generic ingredient in POMALYST is pomalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pomalidomide profile page.

JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.

This drug has ninety-two patent family members in thirty-seven countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

QBREXZA is a drug marketed by Dermira Inc. There are eight patents protecting this drug.

This drug has twenty-two patent family members in twelve countries.

The generic ingredient in QBREXZA is glycopyrronium tosylate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the glycopyrronium tosylate profile page.

GATTEX KIT is a drug marketed by Nps Pharms Inc. There are twenty-one patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-two patent family members in eighteen countries. There has been litigation on patents covering GATTEX KIT

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the teduglutide recombinant profile page.